Eupraxia Pharmaceuticals Inc.
EPRX
$3.27
-$0.0092-0.28%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 3.60M | 2.22M | 2.58M | 2.52M | 2.44M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 7.48M | 6.27M | 6.56M | 6.69M | 11.98M |
Operating Income | -7.48M | -6.27M | -6.56M | -6.69M | -11.98M |
Income Before Tax | -7.53M | -5.99M | -6.07M | -6.15M | -10.57M |
Income Tax Expenses | 1.80K | -- | -5.00K | 5.00K | 36.40K |
Earnings from Continuing Operations | -7.53M | -5.99M | -6.06M | -6.16M | -10.61M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | 23.40K | 48.00K | 56.70K | 113.90K | 380.40K |
Net Income | -7.51M | -5.94M | -6.01M | -6.04M | -10.23M |
EBIT | -7.48M | -6.27M | -6.56M | -6.69M | -11.98M |
EBITDA | -14.83M | -6.25M | -6.53M | -6.67M | -11.95M |
EPS Basic | -0.43 | -0.17 | -0.17 | -0.21 | -0.37 |
Normalized Basic EPS | -0.13 | -0.10 | -0.11 | -0.13 | -0.23 |
EPS Diluted | -0.44 | -0.17 | -0.17 | -0.21 | -0.37 |
Normalized Diluted EPS | -0.13 | -0.10 | -0.11 | -0.13 | -0.23 |
Average Basic Shares Outstanding | 35.64M | 35.62M | 35.62M | 28.81M | 27.31M |
Average Diluted Shares Outstanding | 35.64M | 35.62M | 35.62M | 28.81M | 27.31M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |